ASAleksandr Siniaev

Aleksandr Siniaev

*This is an algorithmically generated author record based on publicly available information.

Aleksandr Siniaev has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification

    by Nikita Volkov, Ivan Moiseev, Maria Krivitskaya, Dmitrii Zhogolev, Maria Vladovskaya, Yulia Vlasova, Sergey Bondarenko, Tatiana Rudakova, Svetlana Ziganshina, Aleksandr Siniaev, et al.

    Background: Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a rare but highly fatal complication after allogeneic hematopoietic cell transplantation (allo‐HCT), frequently diagnosed under conditions of clinical uncertainty. We aimed to characterize post‐transplant sHLH/MAS and to identify clinically accessible factors associated with early mortality. Methods: We retrospectively analyzed adult patients who developed sHLH/MAS after allo‐HCT between 2018 and 2025. Inclusion required an HScore ≥ 169. Overall survival within 60 days from sHLH/MAS onset was the primary endpoint. Clinical and laboratory variables were evaluated using Cox proportional‐hazards models, and patients were stratified according to the number of adverse prognostic factors identified. Results: Seventy‐two patients met inclusion criteria. Median time from allo‐HCT to sHLH/MAS onset was 22 days. Sixty‐day overall survival was poor. In univariable and multivariable analyses, vasopressor‐dependent sepsis (HR 7.77, p < 0.001) and ferritin > 15 000 μg/L (HR 3.48, p = 0.002) were independently associated with early mortality. Stratification based on these two factors separated patients into low‐, intermediate‐, and high‐risk groups with 60‐day survival of 92%, 52%, and 9%, respectively ( p < 0.001). Conclusions: Post‐transplant sHLH/MAS is associated with extremely high early mortality. Vasopressor‐dependent sepsis and extreme hyperferritinemia identify patients at particularly high risk. These findings require confirmation in independent cohorts.

  • Impact of prior COVID‐19 infection on allogeneic hematopoietic stem cell transplantation outcomes

    by Aleksandr Siniaev, Marina Popova, Yulia Rogacheva, Valeria Ianbukhtina, Egor Kulagin, Maria Vladovskaya, Sergey Bondarenko, Ivan Moiseev, Alexander D. Kulagin

    There are limited data on outcomes of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in recipients with prior COVID‐19 infection. This single‐center retrospective study included 54 adult patients who received allo‐HSCT from July 2020 to September 2021 after previous COVID‐19 infection and 122 control group patients without a history of COVID‐19 who underwent HSCT during the same period, with a median follow‐up of 17 months. Median time from COVID‐19 to allo‐HSCT was 211 days. The incidence of main complications in the post‐transplant period was not significantly different between the two groups: deep vein thrombosis (p = .85), TMA (p = .8), VOD (p = .25), bloodstream infections (p = .21), pneumonia of any etiology (p = .41), viral infections (p = .85), invasive fungal disease (p = .08). The 2‐year non‐relapse mortality, relapse incidence, overall survival, and progression‐free survival also were comparable in the study and the control groups: 22% (95% CI 10.5–36.2) versus 26.3% (95% CI 18.7–34.6) p = .4; 15.6% (95% CI 7.3–26.9) versus 23.6% (95% CI 16.0–32.3) p = .39; 67.9% (95% CI 50.4–80.3) versus 59.8% (95% CI 50.2–68.1) p = .24 and 62.3% (95% CI 45.5–75.3) versus 49.9% (95% CI 40.0–59.1) p = .18, respectively. The history of previous COVID‐19 infection did not affect the results of allo‐HSCT.


  • Open Access

    Mechanisms of central nervous system damage in COVID-19

    by V. V. Rassokhin, E. I. Svetashova, A. A. Shcherbakov, A. Yu. Polushin, M. A. Kucher, I. V. Kazantsev, O. V. Goloshchapov, R. V. Klementieva, A. A. Sinyaev, V. N. Ovechkina, et al.

    The issues of diagnosis and treatment of nervous system damage in the new coronavirus infection (COVID-19) remain relevant, regardless of information and experience in treating such patients, accumulated nowadays. The review contains updated data on the ways of SARS-CoV-2 invasion, examines mechanisms of central nervous system damage: direct virus-induced damage, immune dysfunction, excessive thrombo-inflammation, coagulation disorder, cytokine and metabolic imbalance, hypoxia, etc.; it presents clinical examples with one variant of damage — the development of Guillain-Barre syndrome that, to some extent, allows to confirm the virus neurotropism. Doctors’ knowledge about this infection is constantly expanding, new information appears on its various neuropsychiatric effects during an acute period and post-COVID syndrome, on symptoms, treatment and prevention strategy. These data enables to understand better the reasons for developing the main clinical manifestations, from a headache or myalgia to more severe symptoms, such as a stroke, psychosis and anosmia, severity and reversibility of their course. Although several hypothesis of CNS damage pathogenesis in COVID-19 are being discussed, the unified pathophysiological mechanism of many dysfunctions remains unclear, and, probably, additional factors, such as social isolation during a pandemic, presence and treatment in the intensive care unit, premorbid somatic status of a patient, contribute to the development of some registered nervous system disorders.

  • Clinical Outcomes in Patients With COVID-19 and Hematologic Disease

    by Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, et al.